Session Title: Bringing innovative CKD treatments to patients without delay: Barriers and Solutions
Organized by: AstraZeneca
Session Description:
In recent years, advances in understanding the pathophysiology of kidney diseases, including chronic kidney disease (CKD), have accelerated the development of new drugs. On the other hand, in some regions, gaps in new drug approvals persist, and the 'drug lag' has yet to be resolved.
In addition to the inherent difficulties in establishing evidence specific to the renal field, challenges remain regarding the selection and interpretation of evaluation metrics in various clinical trials and regulatory approvals. Discussions have recently intensified regarding the utilization of new endpoints, such as HCE (Hierarchical Composite Endpoint) and eGFR slope, and the promotion of clinical trials. This symposium aims to contribute to the advancement of renal disease through lectures and discussions informed by new evaluation metrics and the latest clinical research trends.
Learning Objectives:
1. Audience understands existing regulatory barriers to prompt drug approval for kidney diseases and its potential solutions (HCE/eGFR slope)
2. Audience understands the existing data on HCE/eGFR slope and able to apply to clinical practice.
| Time | Session |
|---|---|
|
8:10 a.m.
8:20 a.m.
|
|
|
8:20 a.m.
8:30 a.m.
|
|
|
8:30 a.m.
8:40 a.m.
|
|
|
8:40 a.m.
9:10 a.m.
|
|